Eupraxia Pharmaceuticals Reports Promising Trial Results
Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals has announced promising results from their RESOLVE trial ...
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...
Business Insider13h
Eupraxia reports data from RESOLVE Phase 1b/2a trial
Eupraxia Pharmaceuticals (EPRX)announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic ...
clinicaladvisor.com4d
Biologic Therapies for Psoriasis Linked to Increased GI Adverse Events
Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.
EuropaWire4d
Tezspire Shows Promise in Reducing Nasal Polyp Symptoms in Phase III Trial for Chronic Rhinosinusitis
17,18 TSLP is released in response to multiple triggers (including allergens, viruses and other airborne particles) ...
Pharmaceutical Technology4d
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...
Daily5d
Sanofi, Regeneron Dupixent approved in EU for young children with eosinophilic esophagitis
Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) ...
Pharmabiz5d
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...
EuropaWire6d
EMA Approves Dupixent as First-Ever Treatment for Young Children with Eosinophilic Esophagitis in the EU
The European Medicines Agency has approved Dupixent as the first treatment for eosinophilic esophagitis (EoE) in young children aged one to 11, m ...
The Pharma Letter6d
Another Dupixent approval in the EU
French pharma major Sanofi’s Dupixent (dupilumab), which notched up sales of 3.5 billion euros ($3.8 billion) in ...
PharmiWeb6d
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically, the approval covers children aged one to ...